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Abstract
Background: The major metabolic complications of obesity and type 2 diabetes may be prevented and managed
with dietary modification. The use of sweeteners that provide little or no calories may help to achieve this
objective.
Methods: We did a systematic review and network meta-analysis of the comparative effectiveness of sweetener
additives using Bayesian techniques. MEDLINE, EMBASE, CENTRAL and CAB Global were searched to January 2011.
Randomized trials comparing sweeteners in obese, diabetic, and healthy populations were selected. Outcomes of
interest included weight change, energy intake, lipids, glycated hemoglobin, markers of insulin resistance and
glycemic response. Evidence-based items potentially indicating risk of bias were assessed.
Results: Of 3,666 citations, we identified 53 eligible randomized controlled trials with 1,126 participants. In diabetic
participants, fructose reduced 2-hour blood glucose concentrations by 4.81 mmol/L (95% CI 3.29, 6.34) compared
to glucose. Two-hour blood glucose concentration data comparing hypocaloric sweeteners to sucrose or high
fructose corn syrup were inconclusive. Based on two ≤10-week trials, we found that non-caloric sweeteners
reduced energy intake compared to the sucrose groups by approximately 250-500 kcal/day (95% CI 153, 806). One
trial found that participants in the non-caloric sweetener group had a decrease in body mass index compared to
an increase in body mass index in the sucrose group (-0.40 vs 0.50 kg/m
2, and -1.00 vs 1.60 kg/m
2, respectively).
No randomized controlled trials showed that high fructose corn syrup or fructose increased levels of cholesterol
relative to other sweeteners.
Conclusions: Considering the public health importance of obesity and its consequences; the clearly relevant role
of diet in the pathogenesis and maintenance of obesity; and the billions of dollars spent on non-caloric
sweeteners, little high-quality clinical research has been done. Studies are needed to determine the role of
hypocaloric sweeteners in a wider population health strategy to prevent, reduce and manage obesity and its
consequences.
Background
Non-caloric sweeteners have been available commer-
cially since the late 1800s [1] and their use in food pro-
ducts and as table-top sweeteners is increasing -
perhaps due in part to aggressive marketing promoting
their capacity to induce weight loss and weight mainte-
nance [2,3]. In 2007, non-caloric and/or high-intensity
sweeteners accounted for 16% of the US sweetener
market (approximately 0.5 billion USD [4]) and pro-
jected sales of these products are expected to exceed
one billion USD by 2014 [5].
Sugar alcohols can also be used as sweetener additives
and provide less calories per gram than saccharides
(sugars). However because sugar alcohols cause gastro-
intestinal symptoms in some individuals due to incom-
plete absorption in the small intestine, they may be used
less frequently than saccharides. A variety of different
saccharides is commonly used to sweeten foods, such as
sucrose, fructose, glucose, maltose, isomaltulose, and
fructooligosaccharide (FOS). FOS has half the calories
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recently, fructose (a highly commercially used sweetener
used in combination with glucose as high fructose corn
syrup (HFCS)) has been controversially linked with
hypertriglyceridemia [6].
The effects of different sweeteners on clinically rele-
vant outcomes such as weight management, blood glu-
cose and lipids have been incompletely studied. The
main metabolic complications of obesity and type 2 dia-
betes may be prevented and managed in full or in part
with dietary modification, including the use of sweet-
eners that provide little or no calories (hypocaloric
sweeteners) [7-10].
This review systematically summarizes the available
randomized trial evidence to determine the comparative
effectiveness of sweetener additives (non-caloric, sugar
alcohols, and saccharides; Table 1) in food.
Methods
This systematic review was conducted and reported
according to guidelines [11].
Data sources and searches
We did a comprehensive search designed by a MLIS-
trained librarian to identify all randomized controlled
trials (RCTs) comparing sweeteners in generally healthy,
overweight/obese and/or diabetic participants. We
included only trials published in English as full peer-
reviewed manuscripts. MEDLINE (1950 to January 13,
2011), EMBASE (1980 to January 13, 2011), CENTRAL
(January 13, 2011), and CAB (January 13, 2011) were
searched. No existing systematic reviews were found.
The specific strategies used are provided in Additional
File 1. The citations and abstracts were screened by two
reviewers to identify pertinent trials. Any study consid-
ered potentially relevant by one or both reviewers was
retrieved for further consideration.
Study selection
We considered non-caloric sweeteners to include high-
intensity caloric sweeteners that are functionally non-
caloric simply due to extremely low doses (for example,
aspartame). Each potentially relevant study was
Table 1 Description of sweeteners
Sweetener
Commercial products
Nutritive, kcal/g Sweetness intensity,
relative to sucrose
Non-caloric
Acesulfame-K [83-85]
Sunett
®
0 200
Aspartame [83-86]
Equal
®, NutraSweet
®
4 180
Cyclamate [83-85] 0 30-50
Saccharin [83-85]
Sweet’N Low
®, Sugar Twin
®, Hermesetas
®
0 300-500
Sucralose [83-85]
Splenda
®a
0 600
Sugar alcohol
Hydrogenated starch hydrolysate (HSH) [85] ≤3 0.4-0.9
Lycasin [87] 2.4 0.75
Maltitol [85] 3 0.9
Sorbitol [85,86] 2.6 0.6
Saccharide
Fructooligosaccharides (FOS) [88] 2 0.3-0.6
Fructose [85,86,89] 4 1-2
Glucose [86,89] ≥ 4 0.5-1
High fructose corn syrup (HFCS) [85,89]
Varieties: HFCS 55, HFCS 42, HFCS 90
≥ 4~ 1
Honey [90] ≥ 4 1-1.5
Isomaltulose [88,91]
Palatinose
4 0.5
Maltose [86,89] ≥ 4 0.5
Sucromalt [88] 4 0.7
Sucrose [86,89] 4 1 (reference)
Tagatose [83] 1.5 0.9
Trehalose [92] 4 0.45
aSplenda also contains maltodextrin and sometimes dextrose which are both nutritive
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the review using predetermined eligibility criteria. Dis-
agreements were resolved by consultation with a third
party. Trials with healthy, overweight/obese, and/or dia-
betic adult (≥ 16 years old) participants meeting the fol-
lowing criteria were eligible for inclusion: parallel or
crossover RCTs; weight change, energy intake, lipids,
glycated hemoglobin (HbA1C), or insulin resistance
were reported; had at least two groups comparing differ-
ent sweeteners (for example, glucose, fructose, sucrose,
other saccharides, sugar alcohols, non-caloric sweet-
eners: aspartame, saccharin, stevioside, sucralose); and
where follow-up was at least one week in duration (see
the Box in Additional File 1 for study selection sum-
mary). RCTs measuring 2-hour blood (serum or plasma)
glucose responses in similar populations without the fol-
low-up requirement were also reviewed. All outcomes
selected for study (including weight change) are reversi-
ble and thus (providing that order was randomly
assigned), a cross-over design should be appropriate.
Trials with less than ten participants per group were
excluded to improve the efficiency of the work without
an appreciable loss of power, and with the possible elim-
ination of some small study bias. Trials aimed at evalu-
ating exercise performance or memory enhancement
were excluded. Trials with placebo controls were also
excluded as we aimed to investigate comparative effec-
tiveness of different sweeteners, as opposed to exploring
the implications of avoiding sweeteners altogether.
Data extraction and quality assessment
A standardized data extraction method was performed
by a single reviewer. A second reviewer checked the
extracted data for accuracy. The following properties of
each trial were recorded in a database: trial characteris-
tics (country, design, sample size, duration of follow-up);
participants (age, gender, co-morbidity (obesity, diabetes
mellitus - type 1 and 2), baseline body mass index
(BMI), diabetic therapy (insulin, oral antihyperglycemic
agents, diet, and so on); sweetener characteristics (type,
quantity, schedule); diet (that is, daily caloric content by
macronutrient/fiber content); and outcomes. Outcomes
included weight change (absolute, BMI), energy intake,
lipid measures (total cholesterol, triglycerides, high den-
sity lipoprotein (HDL), low density lipoprotein (LDL)),
HbA1C, insulin resistance (for example, Homeostatic
Model Assessment (HOMA) index), and 2-hour blood
glucose (with or without meals).
Risk of bias was assessed using items known to be
associated with the magnitude of results (that is, method
of randomization, double-blinding, description of with-
drawals/dropouts, and allocation concealment) [12,13].
Source of funding was also extracted given its potential
to introduce bias [14].
Data synthesis and analysis
Data were analyzed using Stata 11.1 (http://www.stata.
com). Missing standard deviations (SDs) were imputed
using the maximum value reported in any included
study [15]. Missing correlations for change from base-
line and for differences between crossover trial periods
were assigned a value of 0.63, the maximum reported
value in the included studies. Changes from baseline
means were used in place of final means in parallel ran-
domized trials. For weight change, the baseline value
prior to the immediate period was used. The mean dif-
ference (MD) was used to summarize outcomes. Due to
expected diversity between studies, we decided ap r i o r i
to combine results using a random effects model (Stata
command: metan). Additionally we planned to examine
the association between certain variables (population,
dose, diet, age, gender, and bias criteria) and the effect
of specific sweeteners on outcomes, and publication bias
with weighted regression [16], however the available
comparisons were too sparse to pool trials with out-
comes of one week or less. For 2-hour responses, we
pooled comparisons by type of sweetener and ordered
the matrix tables by expected order of efficacy [17] (that
is, non-caloric sweeteners, sugar alcohols, other sacchar-
ides, fructose, sucrose, and glucose). Statistical heteroge-
neity was quantified using the τ
2 statistic (between-study
variance) [18]. Furthermore, we explored comparative
effectiveness of sweeteners on 2-hour responses using
network meta-analysis [19] (specifically, Markov chain
Monte Carlo [MCMC] methods within a Bayesian frame-
work) in WinBugs (http://www.mrc-bsu.cam.ac.uk/bugs;
code was obtained from Ades et al.[ 2 0 ] ) .N e t w o r ka n a l y -
sis extends meta-analysis from simply pooling directly
compared treatments (direct evidence) to pooling data
from studies not directly compared but linked via one or
more common comparators (indirect evidence) by assum-
ing consistency of the evidence [19]. Therefore, this tech-
nique facilitates the comparison of any two sweeteners
not directly compared in any one study. We used non-
informative prior distributions: uniform for the between-
study variance (range 0 to 20) and Gaussian for the other
parameters (mean 0 and variance 10,000). All chains
were run for 10,000 iterations after 1,000 burn-in itera-
tions. Convergence of the MCMC algorithm was assessed
using autocorrelation plots. By-population results were
generated. Inconsistency in the network (disagreement
between direct and mixed evidence) was measured using
back-calculations [21]. Ninety-five present Bayesian cred-
ible intervals are reported.
Results
Quantity of research available
The searches identified 3,666 unique records with no
trials found outside the main literature searches. After
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evaluation (Figure 1) and of these 440 articles were
excluded resulting in 53 trials (from 51 publications)
that met the selection criteria. Disagreements about the
inclusion of studies occurred in 11% of the articles
(kappa = 0.71). Fourteen were ultimately included. The
remaining were excluded for the following reasons: thir-
teen with no relevant control group, nine with no
relevant population, five with no relevant intervention
group, four due to study design, four for small sample
size, and one for no usable data. The sweeteners studied
in eligible trials are described in Table 1.
Characteristics of 2-hour response trials
Of the forty included trials with 2-hour response data (703
participants; Table 2), three trials compared a non-caloric
Potentially relevant records identified and screened for retrieval (n=3666)
Citations excluded (n=3175)
Not relevant (n=3114)
No translator (n=58)
Not retrievable (n=3)
Articles retrieved for detailed evaluation (n=491)
Articles excluded (n=440)
No relevant control group (n=114)
No original research (n=77)
Intervention (n=79)
No relevant study design (n=58)
Population (n=46)
Sample size (n=44)
No usable data (n=7)
No relevant outcome (n=13)
Not published (n=1)
Multiple publication (n=1)
Primary articles included in the systematic review (n=51)
Trials included in the systematic review (n=53)
1 week weight management, blood glucose and lipids trials (n=13)
2-hour response trials (n=40)
Duplicated records (n=1292)
Potentially relevant records identified through database searching (n=4958)
and through other sources (n=0)
Figure 1 Flow diagram of trials considered for inclusion. This flow diagram depicts each step in the process of trial selection.
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Page 4 of 18Table 2 Description of included 2-hour response randomized trials
Author,
Year,
Country
Population,
Mean BMI (kg/m
2)
Sweetener 1:
Type,
Quantity
Sweetener
2:
Type,
Quantity
Medium Study
design,
Follow-up,
Sample
size
Mean
age
(y),
%
female
Allocation
concealment,
Jadad score,
Funding
Non-caloric vs Saccharide
Gonzalez-Ortiz
[24]
2009
Mexico
General
23
Sucralose (Enterex
Diabetic
®)
45% once
Mixture
b
(Glucerna
SR
®)
50% once
Drink xRCT
21 d
periods
(3d wo)
14
22
64
Unclear
2
-
Prat-Larquemin
[22]
2000
France
General
20
Aspartame
0.27 g once
Sucrose
90 g once
Cheese xRCT
21 d
periods
(1wk wo)
24
23
0
Unclear
3
Mixed
e
Melchior [23]
1991
France
General
21
Aspartame
80mg once
Sucrose
50 g once
Drink xRCT
21 d
periods
10
22
70
Unclear
1
Public
Non-caloric vs Non-caloric
Horwitz [25]
1988
US
55% General/45% DM2
<2 5
Aspartame
400 mg once
Saccharin
135 mg
once
Unsweetened
drink
xRCT
21 d
periods
(1wk wo)
22
41
77
Unclear
1
Private
Sugar Alcohol vs Saccharide
Rizkalla [28]
2002
France
50% General
25
50% DM2
27
Lycasin
50 g once
Glucose
50 g once
None xRCT
21 d
periods
(1wk wo)
12
40
0
Unclear
2
Private
Nguyen [26]
1993
France
General
-
Lycasin
20 g once
Sorbitol
20 g once
Xylitol
20 g once
Maltitol
20 g once
Glucose
20 g once
None xRCT
51 d
periods
(1wk wo)
10
33
50
Unclear
1
Private
Wheeler [29]
1990
US
33% General
24
f
33% DM2
32
33% DM1
23
HSH6075
50 g once
HSH5875
50 g once
Glucose
50 g once
None xRCT
31 d
periods
18
47
50
Unclear
2
Mixed
Hassinger [27]
1981
Germany
DM1
-
Xylitol
30 g once
Sucrose
30 g once
Meal xRCT
21 d
periods
14
29
-
Unclear
1
Private
Saccharide vs Saccharide
Maki [30]
2009
US
Obese
35
Trehalose
75 g once
Trehalose/
Fructose
75 g once
Glucose
75 g once
None xRCT
31 d
periods
21
50
0
Unclear
3
Private
Teff [31]
2009
US
Obese
35
Fructose
30%
Glucose
30%
Meals & Drinks xRCT
22 d
periods
(1mo wo)
17
33
47
Unclear
1
Public
Van Can [52]
2009
Netherlands
Overweight
28
Isomaltulose
75 g once
Sucrose
75 g once
None xRCT
21 d
periods
(1wk wo)
10
31
20
Unclear
1
Private
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Grysman [58] A
2008
Canada
General
24
Sucromalt
50 g once
HFCS42
50 g once
None xRCT
21 d
periods
10
28
30
Unclear
2
Private
Grysman [58] B
2008
Canada
General
24
Sucromalt
80 g once
HFCS42
80 g once
None xRCT
21 d
periods
10
25
50
Unclear
2
Private
Grysman [58] C
2008
Canada
General
24
Sucromalt
50 g once
HFCS42
50 g once
Glucose
50 g once
Meal xRCT
31 d
periods
20
37
60
Unclear
2
Private
Munstedt [59]
2008
Germany
General
23
Glucose/Fructose
a
155 g once
Honey
221 g once
None xRCT
21 d
periods
(1wk wo)
10
28
0
Unclear
2
-
Stanhope [54]
2008
US
General
25
HFCS55
25% thrice
Sucrose
25% thrice
3 Meals xRCT
21 d
periods
(1mo wo)
34
35
47
Unclear
1
Mixed
Bowen [32]
2007
Australia
Overweight/
Obese
33
Fructose
50 g once
Glucose
50 g once
Drink xRCT
21 d
periods
(7d wo)
28
57
0
Unclear
4
Mixed
Chong [33]
2007
UK
General
25
Fructose
0.75 g/kg once
Glucose
0.75 g/kg
once
Drink xRCT
21 d
periods
(6wk wo)
14
43
43
Unclear
1
Mixed
Melanson [55]
2007
US
General
22
HFCS55
30% TID
Sucrose
30% TID
3 Meals xRCT
22 d
periods
(6wk wo)
30
33
100
Unclear
2
Private
Visvanathan [34]
2005
Australia
General
26
Sucrose
50 g once
Fructose
50 g once
Glucose
50 g once
None xRCT
31 d
periods
(3d wo)
10
72
60
Unclear
1
Public
Teff [35]
2004
US
General
23
Fructose
30% TID
Glucose
30% TID
3 Meals xRCT
22 d
periods
(1mo wo)
12
25
100
Unclear
1
Mixed
Qin [53]
2003
Japan
General
23
Maltose
75 g QIDx4h
Sucrose
75 g
QIDx4h
None xRCT
21 d
periods
(1wk wo)
10
22
0
Unclear
1
-
Vozzo [36]
2002
Australia
50% IGT/50% DM2
31
Fructose
75 g once
Glucose
75 g once
None xRCT
21 d
periods
(5d wo)
20
56
40
Unclear
1
Mixed
Spiller [37]
1998
US
General
-
Sucrose
90 g once
Glucose
90 g once
None xRCT
21 d
periods
(1wk wo)
10
29
50
Unclear
1
Private
Stewart [38]
1997
Canada
General
20-27
Fructose
30 g SID
Glucose
33.5 g SID
Meal xRCT
21 d
periods
13
25
0
Unclear
1
Private
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Blaak [39]
1996
Netherlands
General
-
Sucrose
75 g once
Fructose
75 g once
Glucose
75 g once
None xRCT
31 d
periods
(1wk wo)
10
28
0
Unclear
1
Mixed
Fukagawa [40]
1995
US
General
-
Fructose
75 g once
d
Glucose
75 g once
None xRCT
21 d
periods
16
47
38
Unclear
1
Public
Schwarz [41]
1992
Switzerland
43% General
21
57% Overweight
30
Fructose
75 g once
Glucose
75 g once
Meal xRCT
21 d
periods
(4d wo)
23
25
100
Unclear
1
Mixed
Bukar [42]
1990
US
DM2
-
HFCS
27 g (12.2 g Fructose/
14.8 g Glucose) once
Sucrose
33.5 g once
Glucose
50 g once
HFCS: Tofu frozen
dessert
Sucrose: Ice cream
Glucose: None
xRCT
31 d
periods
(2d wo)
12
51
50
Unclear
1
-
Georgakopoulos
[43]
1990
Greece
General
-
Sucrose
20 g once
Glucose
20 g once
None xRCT
21 d
periods
(3d wo)
17
Range
25-40
29
Unclear
1
-
Kawai [56]
1989
Japan
50% General
20
50% DM2
23
Isomaltulose
50 g once
Sucrose
50 g once
None xRCT
21 d
periods
(2d wo)
20
39
30
Unclear
1
Mixed
Schwarz [44]
1989
Switzerland
General
21
Fructose
75 g once
Glucose
75 g once
Drink xRCT
21 d
periods
(4d wo)
20
23
50
Unclear
1
Private
Simonson [45]
1988
Switzerland
DM2/General/Obese
f
-
Fructose
75 g once
Glucose
75 g once
None xRCT
21 d
periods
(1wk wo)
37
53
51
Unclear
1
Mixed
Jansen [46]
1987
Netherlands
General
-
Fructose
75 g once
Glucose
75 g once
None xRCT
21 d
periods
(1wk wo)
20
52
50
Unclear
1
Public
Tappy [47]
1986
Switzerland
General
-
Fructose
75 g once
Glucose
75 g once
None xRCT
21 d
periods
(2d wo)
10
27
c
65
c
Unclear
1
Mixed
Erkelens [57]
1985
Netherlands
33% General
f/33% DM2/17%
DM1/17% insulin infusion DM1
-
Honey
(22% Glucose/26%
Fructose) SID
Sucrose
49% SID
White bread &
Cheese
xRCT
21 d
periods
(2d wo)
24
47
46
Unclear
1
Mixed
Samanta [48]
1985
UK
46% General/31% DM1/23%
DM2
-
Honey
26 g once
Sucrose
26 g once
Glucose
26 g once
None xRCT
31 d
periods
26
40
-
Unclear
1
-
Bantle [49]
1983
US
31% General/38% DM1/31%
DM2
-
Sucrose
42 g once
Fructose
42 g once
Glucose
42 g once
Meal xRCT
31 d
periods
32
41
56
Unclear
2
Mixed
Wiebe et al. BMC Medicine 2011, 9:123
http://www.biomedcentral.com/1741-7015/9/123
Page 7 of 18sweetener (aspartame [22,23], or sucralose [24]) to a sac-
charide (fructose [24] or sucrose [22,23]); one trial com-
pared a non-caloric to another non-caloric (aspartame
versus saccharin [25]); four trials compared a sugar alcohol
or a malt containing a sugar alcohol (sorbitol [26], xylitol
[26,27], maltitol [26], Lycasin [26,28], or a hydrogenated
starch hydrolysate (HSH) [29]) to a saccharide (glucose
[26,28,29] or sucrose [27]); and thirty-two trials compared
a saccharide to another saccharide (glucose [30-51], fruc-
tose [31-34,36,38-41,44-47,49,50], mixtures of glucose and
fructose [that is, sucrose [34,37,39,42,43,48-57], HFCS
[42,54,55,58], honey [48,57,59], glucose/fructose equivalent
honey [59]], isomaltulose [52,56], maltose [53], sucromalt
[58], trehalose [30], or a mixture of trehalose and fructose
[30]). Approximately half of the doses for saccharides were
less than the 60 g/day recommended for diabetic patients
on a 2,000 kcal diet; the remainder exceeded 60 g/day
(typically 75 g). All of the doses for sugar alcohols
exceeded the 10 g/day recommendation (range 20 to 50
g), which is aimed at limiting gastrointestinal symptoms.
None of the four non-caloric sweetener groups were
above Acceptable Daily Intake (ADI) values.
Twelve trials included diabetic populations (range
m e a nB M I2 3t o3 2k g / m
2) [25,27-29,36,42,45,48-
50,56,57], five trials exclusively studied overweight or
obese individuals (range mean BMI 28 to 35 kg/m
2)
[30,31,41,45,52], and thirty-five trials included generally
healthy individuals (range mean BMI 20 to 26 kg/m
2).
Median mean age was 35 years (range 22 to 72 years)
and median sex distribution was 47% women.
Sample size ranged from 10 to 37 (median 17), three
studies (8%) had sample sizes ≥ 30 per group and all
were randomized crossover trials. The median Jadad
score was 1 (range 1 to 4); no studies reported conceal-
ing treatment allocation.
2-hour blood glucose response
Table 3 reports the results of the direct meta-analysis
for all populations in the lower triangle and the mixed
evidence from the Bayesian network (Figure 2) in the
upper triangle. The network included 36 trials and 610
participants. The direct evidence from all nine compari-
sons was consistent with the mixed evidence from the
network. There was large heterogeneity between trials
(I
2’s ≥ 77%) for three of seven multi-study direct evi-
dence comparisons. Two of the heterogeneous compari-
sons included a variety of sweeteners (that is, multiple
sugar alcohols (τ
2 = 9.05 (95% CI 2.94,32)), or multiple
other sugars (τ
2 = 1.72 (0.37,1.48))) within one category.
In the fructose versus glucose comparison, six trials
were responsible for the heterogeneity (τ
2 =1 . 4 0
(0.68,1.50)). Three [36,45,50] were subgroups of diabetic
participants; they increased the magnitude of the mean
difference. The other three trials [32,33,46] showed
important differences prior to the 2-hour time point
(data not shown) but at two hours showed little or no
difference between sweeteners. The single estimate of
heterogeneity (τ
2) for the network meta-analysis was
0.65 (95% CI 0.35,1.10).
Reporting the mixed evidence, two comparisons: fruc-
tose versus sucrose (MD -1.12 mmol/L (-1.95,-0.27)),
and fructose versus glucose (-1.56 mmol/L (-2.18,-1.02))
were statistically significant, all favoring fructose, but
neither of the confidence limits excluded the possibility
of non-clinically relevant differences (< 1·15 mmol/L -
calculation based on a clinical important difference of
Table 2 Description of included 2-hour response randomized trials (Continued)
Crapo [50]
1982
US
38% General/23% IGT
f/38%
DM2
-
Sucrose
63 g once
Sucrose
52 g once
Fructose
63 g once
Fructose
52 g once
Glucose
69.9 g once
Sucrose &
Fructose 63 g:
cake
Sucrose &
Fructose 52 g: ice
cream
None
xRCT
51 d
periods
(1d wo)
26
43
42
Unclear
1
Mixed
Mann [51]
1971
South Africa
General
-
Sucrose
60 g once
Glucose
60 g once
Meal xRCT
21 d
periods
(2d wo)
19
Range
20-58
0
Unclear
1
Public
DM1, type 1 diabetes mellitus; DM2, type 2 diabetes mellitus; IGT, impaired glucose tolerance; UK, United Kingdom; US, United States; HFCS, high fructose corn
syrup; FOS, fructooligosaccharide; SID, once a day; BID, twice a day; TID, three times a day; QID, four times a day; carb, carbohydrate; xRCT, randomized crossover
trial; RCT, parallel randomized controlled trial; wo, washout; max, maximum “-” means the value was not reported in the study, and not described
a’comparable Honey’
bcontains isomaltulose, fructose, Sucromalt
® (sucrose, maltose), and FOS
capproximate because it includes 7 people from other studies written up in the same article
dfactorial trial including 300 mg caffeine or 300 mg vitamin C
eboth public and private sources of funding
fgroup of participants dropped due to low group sample size
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Page 8 of 18Table 3 Mean difference in serum glucose (mmol/L) at 2 hours post-sweetener consumption and overnight fast in all
participants
Non-
caloric
0.05
0.98
(-1.24,3.25)
τ
2 =0.65 (0.35,1.10)
0.16
(-1.46,1.80)
consistent
1.19
(-0.56,2.94)
0.07
(-1.45,1.61)
consistent
-0.37
(-2.07,1.29)
- Sugar
alcohols
0.38
-0.83
(-2.66,1.03)
0.21
(-1.47,1.84)
-0.93
(-2.56,0.70)
consistent
-1.37
(-2.96,0.18)
consistent
-0.40
(-0.79,-0.01)
N=1
- Other
sugars
0.01
1.03
(-0.13,2.20)
-0.09
(-1.00,0.81)
consistent
-0.55
(-1.61,0.50)
consistent
-- - Fructose
0.55
-1.12
(-1.95,-0.27)
consistent
-1.56
(-2.18,-1.02)
consistent
0.30
(-1.99,2.58)
N=2I
2 =0
τ
2 =0
0.41
(-2.44,3.26)
N=1
-0.28
(-1.67,1.11)
N=7I
2 =8 4
τ
2 = 1.72
(0.37,1.48)
-0.41
(-1.30,0.47)
N=9I
2 =1 1
τ
2 = 0.17
(0.58,2.41)
Sucrose/
HFCS/
Honey
0
-0.45
(-1.15,0.21)
consistent
- -2.20
(-10.46,6.05)
N=3I
2 =8 5
τ
2 = 9.05
(2.94,32.22)
0.10
(-2.46,2.66)
N=2I
2 =0
τ
2 =0
-1.40
(-2.05,-0.74)
N = 23 I
2 =7 7
τ
2 = 1.4 (0.68,1.50)
-0.31
(-0.53,-0.08)
N = 15 I
2 =0
τ
2 =0
(0,0.28)
Glucose
0
HFCS, high fructose corn syrup
The mixed evidence of the Bayesian network analysis are in the upper triangle and the direct evidence calculated using the REML estimate of τ
2 are in the lower
triangle. Sweeteners are reported in the expected order of efficacy[17] (with the exception of other sugars) from the expected lowest to highest 2-hour glucose
response, with the estimated probability (or rank) listed in the diagonal. Each table cell contains the mean difference (MD) with the accompanying 95%
confidence intervals. In the cells with direct evidence, we also list the number of studies, the I
2 (percent of heterogeneity due to between-study heterogeneity)
and τ
2 (the between-study variance). Blank cells in the lower triangle indicate that no direct evidence was available. In the cells with mixed evidence, we list
whether the mixed evidence was consistent with the available direct evidence. Also, in the first cell of the mixed evidence, we list the single τ
2 estimate for the
mixed evidence. Results are the MD of the expected higher-ranked sweeteners compared to the expected lower-ranked sweeteners (for example, MD of sugar
alcohols versus sucrose is 0.41 and is in column 2, row 5 for the direct results, and is -0.93 and is in column 5, row 2 for the network analysis results). MDs less
than zero favor the expected higher-ranked sweetener (smaller glucose response). For example, sugar alcohols show an increased serum glucose response by
0.41 mmol/L compared to sucrose using the direct evidence. However, sugar alcohols show a decreased serum glucose response by 0.93 mmol/L using the
mixed evidence. However, since both confidence intervals include zero, neither analysis allows a confident judgment about which sweetener is preferable.
Pooled evidence significant at P < 0.05 are presented in bold font. All nine mixed and direct results are consistent.
Sucrose/
HFCS/
Honey
Sugar
alcohols
Glucose Non-caloric*
Other
sugars
Fructose
Figure 2 Network: blood glucose (mmol/L) at 2 hours post-sweetener consumption and overnight fast. HFCS, high fructose corn syrup.
*non-caloric sweetener groups were unavailable in the network with diabetic participants.
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Page 9 of 181% for HbA1C) [60]. The weighted regression test for
publication bias was not significant.
In the subnetwork of 31 trials enrolling participants
without diabetes (446 participants; τ
2 = 3.66 (1.66,7.31);
Appendix Table 1 in Additional File 1), the direct evi-
dence from all 8 comparisons was consistent with the
mixed evidence from the network. The heterogeneity
although reduced remained large between trials (I
2’s ≥
60%) in both of the remaining multi-study direct evi-
dence comparisons. Using the mixed evidence, three
comparisons: fructose versus sucrose (-0.54 mmol/L
(-1.06,-0.03)), fructose versus glucose (-0.89 mmol/L
(-1.21,-0.59)), and fructose versus other sugars (-0.85
mmol/L (-1.47,-0.21)) were statistically significant, all
favoring fructose, but none of the confidence limits
excluded the possibility of non-clinically relevant
differences.
In the subnetwork of ten trials enrolling participants
with diabetes (152 participants; Appendix Table 2 in Addi-
tional File 1), the direct evidence from all six comparisons
was consistent with the mixed evidence from the network.
Note, this network did not include non-caloric sweeteners.
B e c a u s et h ee s t i m a t eo fτ
2 (224 (0.14,139)) did not con-
verge, we report our findings from the direct evidence.
Three direct comparisons were significant and found clini-
cally relevant differences between agents over the entire
confidence interval span: fructose versus glucose in 5 trials
with 52 participants (-4·81 mmol/L (-6·34,-3·29), I
2 = 0%,
τ
2 = 0 (0,7.47)), HSH versus glucose in 1 trial [29] with 12
participants (-6·19 mmol/L (-9·78,-2·60)) and isomaltulose
versus sucrose in 1 trial [52] with 20 participants (-3·44
mmol/L (-5·31,-1·56)).
Characteristics of trials studying effects on weight
management, blood glucose and blood lipids
Of the 13 trials (412 participants; Table 4), 3 trials com-
pared a non-caloric sweetener (aspartame [61], cycla-
mate [62], or a mixture [63]) to sucrose, and 10 trials
compared a saccharide to a different saccharide (glucose
[64-66], fructose [64,65,67], mixtures of glucose and
fructose [that is, sucrose [66-72] or honey [69]], FOS
[71-73], a mixture of isomaltulose and sucrose [68], or
tagatose [70]). No trials evaluated stevioside. Seven trials
did not give any daily diet recommendations; one FOS
trial recommended low-fiber intake [72]; one restricted
added sweeteners to the assigned sweetener [62]; three
trials restricted total energy levels and composition of
macronutrients (55% carbohydrate, 30% fat, 15% pro-
tein) [64,65,67]; and another restricted total energy
levels and the composition to the assigned sweetener
plus calcium caseinate [66]. With three exceptions
[63,64,66], the doses of sweeteners were at or below cur-
rent clinical practice guideline (CPG) recommendations
(10% of total energy intake (for example, 60 g of sucrose
in a 2000 kcal diet) although only three trials [64,65,67]
restricted overall energy intake, therefore further sweet-
ener consumption may have exceeded current recom-
mendations. One trial [63] prescribed sweeteners
(simple carbohydrates) at 25% of total energy intake -
the American Diabetes Association (ADA) 2004 recom-
mended maximum. The earliest trial [66] prescribed
sweeteners at 87% of total energy intake - they were dif-
ferentiating energy availability from energy content.
Four trials were in diabetic populations [62,67,71,73],
seven trials were in generally healthy populations
[61,64-66,68,70,72] and two trials were in overweight/
obese [69] or overweight [63] populations. Mean BMI
levels ranged from 21 to 31 kg/m
2. Median mean age
was 35 years and median sex distribution was 54%
women.
Sample size ranged from 10 to 133 (median 20), 1 had
as a m p l es i z e≥ 30 per group and duration of follow-up
ranged from 1 to 12 weeks (median 4 weeks). Ten were
crossover trials [62,64-67,70-73] and four were parallel
trials [61,63,68,69]. Jadad scores ranged from 1 to 2
(median 1). Twelve of thirteen trials did not report
whether or how treatment assignment was concealed.
One used alternating assignments according to body
weight [70].
Non-caloric versus saccharide: effects on weight
management, blood glucose and blood lipids
Two trials reported change in BMI (Table 5). The 4-
week trial in healthy participants [61] did not find a sig-
nificant loss in BMI in non-caloric sweetener recipients
(-0.3 kg/m
2 (-1.1,0.5), 133 participants). The trial in
overweight participants [63] found a significantly greater
loss in BMI over ten weeks of follow-up in participants
consuming the non-caloric sweetener (-0.9 kg/m
2 (-1.5,-
0.4), 41 participants). Two trials reported absolute
change in weight. One crossover trial was done in type
1 diabetic participants and found no difference in weight
loss between groups over four weeks (0.8 kg (-3.3,4.9),
ten participants [62]). The other trial in overweight par-
ticipants [63] found significantly greater weight loss over
10 weeks in the non-caloric sweetener group (-2.6 kg
(-3.7,-1.5), 41 participants).
Two trials reported energy intake; both reported a sig-
nificant effect of non-caloric sweeteners. The 4-week
trial in generally healthy participants [61] found a signif-
icantly reduced intake of calories in non-caloric sweet-
ener participants (-283 kcal (-414,-153), 133
participants).The trial in overweight participants [63]
also found significantly less energy intake (over one day)
in the non-caloric sweetener group after ten weeks of
follow-up (-491 kcal (-806,-177), 41 participants).
Available trials found no effect of sweetener type on
HbA1C (one trial: -0.02% over four weeks (-0.40,0.30),
Wiebe et al. BMC Medicine 2011, 9:123
http://www.biomedcentral.com/1741-7015/9/123
Page 10 of 18Table 4 Characteristics of included randomized trials with effects on weight management, blood glucose and blood
lipids
Author,
Year,
Country
Population,
Mean BMI
(kg/m
2)
Sweetener 1:
Type,
Quantity (g/d)
Sweetener 2:
Type,
Quantity (g/
d)
Daily Diet
(carbohydrate/
fat/protein)
Study
design,
Follow-up,
Sample
size
Mean age
(y),
% female
Allocation
concealment,
Jadad score,
Funding
Non-caloric versus Saccharide
Reid [61]
2007
UK
General
23
Aspartame
3.56
Sucrose
42
Ad lib RCT
4w k
133
32
100
Unclear
1
Public
Raben [63]
2002
Denmark
Overweight
28
Aspartame/
Acesulfame/
Cyclamate/
Saccharin
0.48-0.67
Sucrose
125-175
Ad lib RCT
10 wk
41
35
85
Unclear
1
Mixed
a
Chantelau [62]
1985
Germany
DM1
<2 5
Cyclamate
348 mg
Sucrose
24
Restricted to no other
added sweeteners however
sucrose-sweetened soft
drinks were discouraged
xRCT
2 4wk
periods
10
Range 25-
43
80
Unclear
1
-
Saccharide versus Saccharide
Okuno [68]
2010
Japan
General
23
Isomaltulose/
Sucrose
40
Sucrose
40
Ad lib RCT
12 wk
50
53
80
Unclear
2
Private
Tudor Ngo
Sock [64]
2010
Netherlands
General
19-25
Fructose
3.5 g/kg FFM
Glucose
3.5 g/kg FFM
Total and distribution of
energy restricted
55/30/15%
xRCT
2 1wk
periods
(2-3wk wo)
11
25
0
Unclear
1
Mixed
Yaghoobi [69]
2008
Iran
Overweight/
Obese
31
Honey
70
Sucrose
70
Ad lib RCT
Max 30d
55
42
56
Unclear
1
Public
Boesch [70]
2001
Switzerland
General
<2 5
Tagatose
45
Sucrose
45
Ad lib xRCT
2 28d
periods
(28d wo)
12
Range 21-
30
0
Inadequate
2
-
Bantle [65]
2000
US
General
25
Fructose
80
(incl 17 g
glucose)
Glucose
80
(incl 15 g
fructose)
Total and distribution of
energy restricted
55/30/15%
xRCT
2 42d
periods
24
41
50
Unclear
1
Public
Luo [71]
2000
Belgium
DM2
28
FOS
20
Sucrose
20
Ad lib xRCT
2 4wk
periods
(2wk wo)
10
57
40
Unclear
1
Private
Alles [73]
1999
Netherlands
DM2
28
FOS
Saccharide
30
Glucose
Saccharide
8
Ad lib xRCT
2 20d
periods
20
59
55
Unclear
1
Mixed
Luo [72]
1996
France
General
21
FOS
20
Sucrose
20
Low-fiber diet
recommended
xRCT
2 4wk
periods
(2wk wo)
12
24
0
Unclear
2
Private
Bantle [67]
1986
US
50% DM1/50%
DM2
-
Sucrose
23%
Fructose
21%
Total and distribution of
energy restricted
55/30/15%
xRCT
28 d
periods
24
43
54
Unclear
1
Mixed
Macdonald [66]
1973
UK
General
-
Sucrose
6.5 g/kg
Glucose
6.5 g/kg
Restricted to
1 g/kg calcium
caseinate
xRCT
2 11d
periods
(2wk wo)
10
Range 20-
25
40
Unclear
1
Private
UK, United Kingdom; US, United States; DM1, type 1 diabetes mellitus; DM2, type 2 diabetes mellitus; HFCS, high fructose corn syrup; FOS, fructooligosaccharide;
FFM, fat free mas;, xRCT, controlled crossover trial; RCT, parallel randomized controlled trial; wo, washout; max, maximum; “-” means the value was not reported
in the study
aBoth public and private sources of funding
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Page 11 of 18ten participants [62]) or the HOMA index (one trial:
-0.20 over ten weeks (-0.58,0.18), forty-one participants
[63]). The trial in ten type 1 diabetic participants [62]
found no effect on total cholesterol, HDL cholesterol, or
triglycerides over the course of four weeks; the other
trial in forty-one overweight participants [63] found no
effect on triglycerides over the course of ten weeks.
Saccharide versus saccharide: effects on weight
management, blood glucose and blood lipids
Two trials reported change in BMI (Table 6); one com-
paring honey to sucrose in overweight/obese partici-
pants over 4 weeks of follow-up [69]; the other
comparing a mixture of isomaltulose and sucrose to
sucrose over 12 weeks of follow-up [68] in healthy parti-
cipants. Neither found a significant difference between
sweeteners. One trial compared FOS to glucose [73]
(three weeks in twenty diabetic participants) and one
trial compared FOS to sucrose [72] (four weeks in
twelve healthy participants), respectively. Neither found
ad i f f e r e n c ei na b s o l u t ew e i g h tc h a n g e .F i v eo t h e rt r i a l s
done in varying populations (including overweight/obese
[69] or healthy populations [64-66,68]) found no differ-
ences in change in absolute weight between sweeteners.
Two trials reported energy intake (FOS compared with
glucose [73] and sucrose [72] respectively, but neither
found a significant difference.
Two trials (one comparing FOS to sucrose [71] and
one comparing isomaltulose/sucrose to sucrose [68])
found no significant effect on HbA1C. However, the lat-
ter [68] found a significant decrease in the HOMA
index among isomaltulose/sucrose recipients (-0.44
(-0.76,-0.12)).
Seven trials reported change in total cholesterol. The
pooled result of two trials [71,72] comparing FOS to
sucrose was statistically significant (0.26 mmol/L
(0.03,0.48), I
2 =0 % ,τ
2 = 0 (0,0.01)), although this conclu-
sion was based on a total of only twenty-two participants.
One trial comparing isomaltulose and sucrose to sucrose
(50 healthy participants over 12 weeks) [68] found a sig-
nificantly smaller increase in total cholesterol for the iso-
maltulose/sucrose group (-0.10 mmol/L (-0.17,-0.02)). No
trials found an effect of sweetener type on LDL choles-
terol or HDL cholesterol. The trial comparing isomaltu-
lose and sucrose to sucrose [68] also found a significant
effect on triglycerides (-0.27 mmol/L (-0.44,-0.10), 0.11
decrease versus 0.16 mmol/L increase). However, four
trials studying other combinations of sweeteners
Table 5 Weight management, blood glucose and blood lipids: Non-caloric versus Sucrose
Non-caloric
sweetener
Population Timepoint (week) No of participants MD (95% CI)
BMI, kg/m
2
Aspartame General 4 133 -0.3 (-1.1,0.5)
Mixture
a Overweight 10 41 -0.9 (-1.5,-0.4)
Weight, kg
Cyclamate DM1 4 10 0.8 (-3.3,4.9)
Mixture Overweight 10 41 -2.6 (-3.7,-1.5)
Day Energy Intake, kcal
Aspartame General 4 133 -283 (-414,-153)
Mixture Overweight 10 41 -491 (-806,-177)
HbA1C, %
Cyclamate DM1 4 10 -0.02 (-0.4,0.3)
HOMA Index
Mixture Overweight 10 41 -0.20 (-0.58,0.18)
Total Cholesterol, mmol/L
Cyclamate DM1 4 10 -0.34 (-0.87,0.19)
HDL Cholesterol, mmol/L
Cyclamate DM1 4 10 -0.05 (-0.32,0.22)
Triglycerides, mmol/L
Cyclamate DM1 4 10 -0.02 (-0.16,0.12)
Mixture Overweight 10 41 -0.26 (-0.85,0.34)
aAspartame, acesulfame, cyclamate, saccharin
DM1, Type 1 Diabetes Mellitus; DM2, Type 2 Diabetes Mellitus; BMI, Body mass index; HbA1C, Glycated haemoglobin; HOMA, Homeostatic Model Assessment;
MD, Mean difference; CI, Confidence interval
Statistically significant results are bolded.
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Page 12 of 18Table 6 Weight management, blood glucose and blood lipids: Saccharide vs Saccharide
Comparison Population Timepoint (week) No of participants MD (95% CI)
BMI, kg/m
2
Honey vs Sucrose Overweight/Obese 4 55 -0.5 (-3.1,2.1)
Isomaltulose/Sucrose vs Sucrose General 12 50 -0.04 (-0.4,0.3)
Weight, kg
Fructose vs Glucose General 6 24 0.1 (-3.4,3.6)
Fructose vs Glucose General 1 11 -0.4 (-3.1,2.3)
FOS vs Glucose DM2 3 20 0.2 (-5.2,5.6)
FOS vs Sucrose General 4 12 1.0 (-2.4,4.4)
Honey vs Sucrose Overweight/Obese 4 55 -1.5 (-6.9,3.9)
Isomaltulose/Sucrose vs Sucrose General 12 50 -0.06 (-0.9,0.8)
Sucrose vs Glucose General 2 10 0.2 (-0.07,0.4)
Energy Intake, kcal
FOS vs Glucose DM2 3 20 -139 (-399,122)
FOS vs Sucrose General 4 12 -56 (-156,43)
HbA1C, %
FOS vs Sucrose DM2 4 10 0.17 (-0.59,0.93)
Isomaltulose/Sucrose vs Sucrose General 12 50 0.01 (-0.05,0.07)
HOMA Index
Isomaltulose/Sucrose vs Sucrose General 12 50 -0.44 (-0.76,-0.12)
Total Cholesterol, mmol/L
Fructose vs Glucose General 1 11 0.10 (-0.24,0.44)
FOS vs Glucose DM2 3 20 0.20 (-0.27,0.67)
FOS vs Sucrose DM2 4 10 0.15 (-0.24,0.54)
FOS vs Sucrose General 4 12 0.31 (0.03,0.59)
Honey vs Sucrose Overweight/Obese 4 55 -0.11 (-0.26,0.05)
Isomaltulose/Sucrose vs Sucrose General 12 50 -0.10 (-0.17,-0.02)
Tagatose vs Sucrose General 4 12 -0.11 (-0.51,0.29)
LDL Cholesterol, mmol/L
Fructose vs Glucose General 1 11 0 (-0.17,0.17)
FOS vs Sucrose DM2 4 10 0.13 (-0.21,0.47)
Honey vs Sucrose Overweight/Obese 4 55 -0.03 (-0.22,0.16)
Isomaltulose/Sucrose vs Sucrose General 12 50 -0.02 (-0.08,0.04)
Tagatose vs Sucrose General 4 12 0.09 (-0.26,0.44)
HDL Cholesterol, mmol/L
Fructose vs Glucose General 1 11 0 (-0.17,0.17)
FOS vs Sucrose General 4 12 -0.06 (-0.14,0.02)
FOS vs Sucrose DM2 4 10 0.07 (-0.03,0.17)
Honey vs Sucrose Overweight/Obese 4 55 0.01 (-0.12,0.14)
Isomaltulose/Sucrose vs Sucrose General 12 50 -0.02 (-0.05,0.01)
Tagatose vs Sucrose General 4 12 -0.17 (-0.28,0.06)
Triglycerides, mmol/L
FOS vs Glucose DM2 3 20 0.12 (-0.30,0.54)
FOS vs Sucrose General 4 12 0.18 (-0.03,0.39)
FOS vs Sucrose DM2 4 10 -0.18 (-0.38,0.02)
Honey vs Sucrose Overweight/Obese 4 55 -0.10 (-0.22,0.02)
Isomaltulose vs Sucrose General 12 50 -0.27 (-0.44,-0.10)
*Aspartame, acesulfame, cyclamate, saccharin
DM1 Type 1 Diabetes Mellitus, DM2 Type 2 Diabetes Mellitus, BMI Body mass index, HbA1C Glycated hemoglobin, HOMA Homeostatic Model Assessment, MD
Mean difference, CI Confidence interval
Statistically significant results are bolded.
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Page 13 of 18[69,71-73] found no effect of sweetener choice on trigly-
ceride levels.
Discussion
To our knowledge, this is the first systematic review of
randomized trial evidence that examines comparative
sweetener effectiveness in diabetic, overweight/obese,
and healthy populations. Despite tremendous interest in
hypocaloric sweeteners as a potential tool to prevent
obesity and its complications, we found little evidence
to support their health benefits as compared to caloric
alternatives. Based on analyses of two trials, we found
that the inclusion of non-caloric sweeteners in the diet
resulted in reduced energy intake compared to the calo-
ric (sucrose) groups - approximately 500 kcal/day less
over 10 weeks or 250 kcal/day over 4 weeks. The longer
of these trials found that those in the non-caloric sweet-
ener group also had a decrease in BMI compared to an
increase in BMI in the sucrose group (-0.40 versus 0.50
kg/m
2,a n d- 1 . 0 0v e r s u s1 . 6 0k g ,r e s p e c t i v e l y )[ 6 3 ] .
Given that the control group was asked to ingest sup-
plemental calories in addition to their regular ad lib
diet, a BMI reduction of approximately1 kg/m
2 over 10
weeks (or 0·1 kg/m
2/ w e e k )m a yb eo v e r l yo p t i m i s t i c .
However, even a reduction in BMI of 0.05 kg/m
2/week
would be clinically relevant if sustained for a year or
more. The remaining analyses comparing non-caloric
and caloric sweeteners were non-significant.
Main findings
￿ 53 randomized controlled trials were included - all
small and largely short-term (only 13 trials with ≥1
week durations)
￿ 2-hour blood glucose (mixed evidence, τ
2 =3 . 6 6
(95% CI 1.66,7.31): fructose versus sucrose (MD
-0.54 mmol/L (-1.06,-0.03)), fructose versus glucose
(-0.89 mmol/L (-1.21,-0.59)), fructose versus other
sugars (-0.85 mmol/L (-1.47,-0.21)) in non-diabetic
participants
￿ 2-hour blood glucose (direct evidence): fructose
versus glucose (-4·81 mmol/L (-6.34,-3.29), I
2 =0 % ,
τ
2 = 0 (0,7.47), 5 trials in 52 diabetic participants)
￿ change in BMI: non-caloric mixture versus sucrose
(MD -0.9 kg/m
2 [-1.5,-0.4], in 41 overweight partici-
pants, over 10 weeks), non-caloric aspartame versus
sucrose (-0.3 kg/m
2 (-1·1,0·5), 133 healthy partici-
pants, over 4 weeks)
￿ energy intake (over one day): non-caloric aspar-
tame versus sucrose (-283 kcal (-414,-153), 133
healthy participants, over 4 weeks), non-caloric mix-
ture versus sucrose (-491 kcal (-806,-177), 41 over-
weight participants, over 10 weeks)
￿ total cholesterol: FOS versus sucrose (0.26 mmol/L
(0.03,0.48), I
2 =0 % ,τ
2 = 0 (0,0.01), 2 trials with a
total of 12 healthy and 10 type 2 diabetic partici-
pants, over 4 weeks)
Head-to-head comparisons between saccharides did
not identify any statistically significant differences. The
confidence limits of these results either included mini-
mally important differences or the group sizes were too
small (< 30) to have good estimates of standard devia-
tion [74]. The one exception was the comparison
between sucrose and FOS, which suggested that total
cholesterol was reduced to a greater extent with sucrose
than with FOS. However, the confidence intervals for
this analysis included values that were not clinically rele-
vant (0.03 to 0.59 mmol/L). There was no evidence that
HFCS or fructose increased levels of cholesterol relative
to other sweeteners.
Although we found that fructose reduced 2-hour
blood glucose concentrations by 4.81 mmol/L compared
to glucose in diabetic participants, data comparing non-
caloric and sugar alcohols to the more commonly used
sucrose or HFCS were inconclusive. Contrary to percep-
tion and current recommendations, no substantive evi-
dence describing important long-term benefits of
hypocaloric sweeteners for diabetic patients were identi-
fied. Also, despite popular belief, no high-quality RCT
evidence was found indicating that fructose causes or
exacerbates hypertriglyceridemia [6].
Although the identified trials were numerous, they
were very small and largely short-term. We found 13
trials with participant follow-up longer than 1 week and
group sizes ≥ 10: 3 that compared non-caloric sweet-
eners to sucrose, and 10 that were head-to-head com-
parisons of saccharides. Ten of 13 trials had a Jadad
score of 1 and none adequately concealed treatment
assignment prior to assignment. Although blinding the
participants would have been impossible in many of the
trials due to taste differences between sweeteners [63],
the reporting of important design descriptors were lar-
gely absent, indicating a substantial risk for bias [12,13].
The longest trial was only 10 weeks - not long enough
to determine whether substituting a non-caloric sweet-
ener for a caloric sweetener is sustainable in daily prac-
tice. To detect an important reduction in weight over at
least one year such as 2.5 kg/m
2 (less than 0.05 kg/m
2/
week) in a RCT would require a minimum of 85 partici-
pants (assumptions: 25% loss-to-follow-up, a = 0.05,
power = 90%, SD = 3 kg/m
2).
Our network meta-analysis had several limitations: 1)
the sugar alcohol and other sugar categories contained
multiple sweeteners that are likely to have different
blood glucose profiles thereby inducing heterogeneity, 2)
power to detect inconsistency is limited by the number
of trials included in each test, and 3) the back-calcula-
tion method used to detect inconsistency involved
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However, we did not detect any inconsistency.
Another limitation was that only three studies
restricted the total energy consumed by each participant.
Therefore, participants may have supplemented energy
lost with non-caloric sweeteners with other food products
- sweetened or otherwise. However, it may be argued that
this is a strength of the trials - in that they reflect what
happens in real world self-management diet practices.
Lastly, and perhaps most importantly, all studies were
small, thereby underestimating standard deviation and as
a result underestimating confidence interval widths and
increasing the likelihood of false-positive findings [74].
D e s p i t et h i s ,t h ec o n f i d e n c ei n t e r v a l sf o rm a n ya n a l y s e s
were wide and did not exclude a minimally important
difference. Small study bias (or publication bias) may also
play a role in our findings concerning longer-term
outcomes.
In theory, substituting non-caloric and lower caloric
sweeteners for simple sugars should reduce energy
intake and thereby the risk of obesity and its conse-
quences. However, there are a number of reasons why
increasing use of non-caloric and lower caloric sweet-
eners might not lead to the expected improvements in
energy regulation. First, use of hypocaloric sweeteners
might not induce weight loss even in the short term.
For example, if reductions in calories due to sweeteners
are offset by increases in caloric intake from other
sources [75,76], or offset by decreases in caloric expen-
diture [77,78]. Although our data suggest that non-calo-
ric sweeteners may lead to clinically relevant weight loss
through reduced energy consumption, this conclusion
was driven by a single trial with a total of 41 partici-
pants. Unlike caloric sweeteners (which may partially
compensate added calories with reduced energy intake
from other sources) [79], non-caloric sweeteners are not
known to suppress appetite, and therefore would not
reduce the motivation to eat. Furthermore, it has been
suggested that the psychobiological signals with non-
caloric sweeteners may directly influence physiological
regulatory mechanisms and thus further reduce their
potential for reducing net energy intake [75,80]. Second,
if calorie reduction is not maintained, short-term reduc-
tions in weight due to the use of hypocaloric sweeteners
might not be sustained. Third, it is possible though
speculative that any health benefits due to weight loss
from non-caloric sweeteners might be wholly or partially
offset by currently unrecognized adverse events due to
their use. The lack of data on the long-term benefits of
non-caloric sweeteners means that it is currently impos-
sible to determine whether these substances will
improve public health.
Conclusions
In summary, despite the public health importance of
obesity, and obesity-related chronic diseases (for exam-
ple, diabetes); the clear role of excessive caloric intake in
these conditions; and the billions of dollars spent on
non-caloric sweeteners [4,5], little high-quality clinical
research has been done to identify the potential harms
and benefits of hypocaloric sweeteners. Since even small
reductions (as little as 6%) in body-weight can prevent
chronic disease [81,82], hypocaloric sweeteners could
play an important role in a wider population health
strategy to prevent, reduce and manage obesity-related
comorbidities. Eliminating unnecessary added sweet-
eners from food products (for example, buns, crackers,
and processed meats) and substituting sugars with lower
calorie sweeteners in foods such as desserts and drinks
could significantly improve health. Long-term, high-
quality, adequately powered randomized controlled trials
are required to confirm this hypothesis by assessing the
clinically relevant outcomes reported in this review.
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